Israel Authorized Anti-SARS-CoV-2 Monoclonal Antibody Treatment for Immunocompromised People

The Israel Ministry of Health today announced it would offer AstraZeneca's anti-SARS-CoV-2 monoclonal antibody (mAbs) treatment Evusheld to people with compromised immune systems who did not get a sufficient antibody boost from the previous COVID-19 vaccination.

The Health Ministry's press statement issued on February 15, 2022, indicates Evusheld will be given regardless of a previous recovery from coronary heart disease or receiving COVID-19 vaccines, provided that two weeks have elapsed since vaccination.

AstraZeneca's Evusheld (AZD7442) (tixagevimab plus cilgavimab) is a Long-Acting mAbs combination that protects severe COVID-19 for up to 12 months.

The U.S. FDA issued an emergency use authorization for Evusheld on December 8, 2021.

As of February 10, 2022, the U.S. NIH OpenData Portal reported Evusheld's in vitro Therapeutic Activity against SARS-CoV-2 virus variants, including Omicron.

Additional mABs breaking news is published at PrecisionVaccinations.com/antibodies.